HDM1702
Sources
registry, as of 2025-06-25Stale
https://clinicaltrials.gov/study/NCT07036172
Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients. Overall status RECRUITING. Phases PHASE3. Lead sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. Enrollment 460. Conditions Obesity Control. This is a 48-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and WEGOVY® in patients with obesity. Eligible participants will be screened and randomized to the experimental
ClinicalTrials.gov NCT07036172 protocol and results modules